DEC 19, 2017 11:11 AM PST

Resolution of the D4 Dopamine Receptor for Drug Discovery

WRITTEN BY: Courtney Schaal

Dopamine receptors are a class of G-protein-couple receptors which span cell membranes to facilitate signal transduction and multiple functions of the cell. G-protein coupled receptors, or GPCRs, also represent a class of highly targeted receptors therapeutically and dopamine receptors are most definitely included in this grouping. Dopamine receptors in specific are an essential part of the central nervous system where they act to facilitate neurotransmission and neuroendocrine signaling. They are integral to many neurological processes such as learning, motor skills, cognition, memory, etc., and alterations in their signaling or function underlies almost every neuropsychiatric disorder. This makes them ideal therapeutic targets in these types of disease. Recently a collaborative group out of Stanford University, California, the University of California, San Francisco, and the University of North Carolina, Chapel Hill, have determined the crystal structure of the D4 dopamine receptor family member. Why is this a good thing? According to this group, “the ability to efficiently exploit structure for specific probe discovery – rapidly moving from elucidating receptor structure to discovering previously unrecognized, selective agonists – testifies to the power of structure based approaches.” This crystal structure also provides a basis by which new therapeutic compounds can be virtually screened to test for binding to the structure, and if any are found to be promising leads, they can be followed up biologically.

Dopamine receptors are implicated in schizophrenia, drug abuse, and Parkinson’s disease to name a few, so identifying new molecules and compounds to combat any or all of them represents much needed progress forward in the field. There are currently many compounds thought to target dopamine receptors, and in specific the D4 family member, but the specificity of these drugs may be less than optimal and the molecular mechanisms underlying is not fully understood. Finding new agonists would not only potentially provide more selective modalities, but would also help us to better understand the biology. In the study mentioned above, the researchers were able to crystalize D4 dopamine receptor in an inactive state while bound to the antipsychotic drug nemonapride with high resolution. This data was then used for computational ligand discovery coupled with biological/pharmacological assays to verify novel, previously unrecognized probes with high selectivity and potency toward this receptor. This has provided the ground work for new therapeutic opportunities in treating a wide range of neuropsychiatric disorders.

Sources: Wikipedia, Science Magazine, Pixabay

About the Author
You May Also Like
NOV 11, 2020
Health & Medicine
A smart path for novel biologics
NOV 11, 2020
A smart path for novel biologics
Introduction  Cell culture is at the heart of the production process for many biopharmaceuticals, but finding the o ...
NOV 12, 2020
Technology
The Crossover of Virtual Reality and Drug Discovery
NOV 12, 2020
The Crossover of Virtual Reality and Drug Discovery
Researchers have recently developed a unique virtual reality (VR) tool that can help in drug development? Particularly, ...
NOV 09, 2020
Drug Discovery & Development
Can Oxidants Slow Down Cellular Aging?
NOV 09, 2020
Can Oxidants Slow Down Cellular Aging?
Oxidants are reactive oxygen species known to be harmful to living organisms at high concentrations and have been linked ...
DEC 01, 2020
Immunology
Scar-Free Healing Starts With Mobilizing the Immune System
DEC 01, 2020
Scar-Free Healing Starts With Mobilizing the Immune System
Thanks to a new hydrogel biomaterial developed by researchers at Duke University, we are one step closer to the holy gra ...
DEC 20, 2020
Genetics & Genomics
A Repurposed Drug Can Treat a Genetic Disorder
DEC 20, 2020
A Repurposed Drug Can Treat a Genetic Disorder
Some researchers have sought to treat genetic diseases by correcting the mutation. But it may be possible to use another ...
DEC 20, 2020
Drug Discovery & Development
Antifungal Drug May Treat Cystic Fibrosis
DEC 20, 2020
Antifungal Drug May Treat Cystic Fibrosis
A fungal-targeting drug was shown to improve symptoms of cystic fibrosis particularly key biomarkers in lung tissue cult ...
Loading Comments...